Colorectal cancer chemotherapeutic drug sensitivity prediction marker probe and application

Abstract

The invention belongs to the technical field of gene detection, and particularly discloses a colorectal cancer chemotherapeutic drug sensitivity prediction marker probe, which comprises a PHLPP probe for detecting PHLPP1 and PHLPP2, the nucleotide sequence of the probe for detecting PHLPP1 is one or more than two in SEQ ID NO.1 to SEQ ID NO.8, and the nucleotide sequence of the probe for detecting PHLPP1 is one or more than two in SEQ ID NO.2. The nucleotide sequence of the probe for detecting the PHLPP2 is one or more than two of SEQ ID NO. 9 to SEQ ID NO. 16. The invention also discloses a detection method of the probe for detecting a colorectal cancer chemotherapeutic drug sensitivity prediction marker, and application of the probe and the detection method thereof in preparation of a detection kit. The probe disclosed by the invention can be used for predicting the sensitivity of a patient to chemotherapeutic drugs such as oxaliplatin, 5-fluorouracil and capecitabine by detecting the PHLPP mRNA level in peripheral blood CTC, and identifying the expression level of PHLPP mRNA in peripheral blood CTC with different phenotypes.

Description

technical field [0001] The invention belongs to the technical field of gene detection, and in particular relates to a colorectal cancer chemotherapeutic drug sensitivity prediction marker probe and application. Background technique [0002] Colorectal cancer (CRC) is one of the major malignant tumors threatening human health. The global cancer data in 2020 shows that the incidence of CRC accounts for 10.0% of all cancers in the world, and the mortality rate accounts for 9.4% of all cancer deaths; in China , the number of new cases of CRC is second only to lung cancer, becoming the second largest cancer. Epidemiological data show that in recent years, the morbidity and mortality of CRC in my country are on the rise. The main clinical manifestations of CRC are changes in bowel habits, abdominal pain, anemia and intestinal bleeding. However, most patients have no obvious symptoms in the early stage, which leads to the fact that CRC patients are mostly in the middle and late s...

AI Technical Summary

Problems solved by technology

The applicant's previous research (Cell Death and Disease (2021) 12:960; https: / / doi.org / 10.1038 / s41419-021-04251-0) found that the downregulation of PHLPP is an important reason for colorectal cancer chemotherapy resistance, The mechanism of drug resistance caused by PHLPP in colorectal cancer was also found out, indicating that PHLPP can be used as a marker for predicting the sensitivity of colorectal cancer chemotherapeutic drugs, but there is currently no clinically feasible kit and corresponding detection method to detect the expression of PHLPP mRNA

Images